Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Fourth generation TKIs for CML: asciminib

Tyrosine kinase inhibitors (TKIs) are the standard first-line treatment for patients with chronic myeloid leukemia (CML). At the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting held in Houston, TX, Michael Mauro, MD, of the Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the recent developments in TKI therapy, including his team’s Phase III trial comparing asciminib, a fourth generation TKI, which acts as an allosteric inhibitor, to bosutinib (NCT03106779). Dr Mauro highlights key unmet needs in CML therapy, such as patients showing resistance or intolerance to TKIs; thus emphasizing the importance of these trials.